AI Article Synopsis
Article Abstract
Parkinson's disease (PD) is a debilitating neurodegenerative disease characterized by tremor, rigidity, bradykinesia, and postural instability, for which there is no effective treatment available till date. Here, we report the development of nonviral vectors specific for neuronal cells that can deliver short interfering RNA (siRNA) against the α-synuclein gene (SNCA), and prevent PD-like symptoms both in vitro and in vivo. These vectors not only help siRNA duplexes cross the blood-brain barrier in mice, but also stabilize these siRNAs leading to a sustainable 60-90% knockdown of α-synuclein protein. Mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine rapidly develop PD-like symptoms which were significantly alleviated when SNCA was knocked down using our vectors. Together, our data not only confirm the central role of α-synuclein in the onset of PD, but also provide a proof of principle that these nonviral vectors can be used as novel tools to design effective strategies to combat central nervous system diseases.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886934 | PMC |
| http://dx.doi.org/10.1038/mt.2015.232 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Suprachoroidal delivery of viral and non-viral vectors for treatment of retinal and choroidal vascular diseases.
Am J Ophthalmol
December 2024
Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD; Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD; Johns Hopkins Translational ImmunoEngineering Center, Johns Hopkins University, Baltimore, MD; Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD; Departments of Chemical & Biomolecular Engineering and Materials Science & Engineering, Johns Hopkins University, Baltimore, MD; Departments of Neurosurgery and Oncology, Johns Hopkins University School of Medicine, Baltimore, MD; Institute for Nanobiotechnology, Johns Hopkins University, Baltimore, MD. Electronic address:
Current treatments for retinal and choroidal neovascular diseases suffer from insufficient durability, including anti-vascular endothelial growth factor-A (VEGF-A) agents. It is, therefore, of interest to explore alternative methods that could allow for robust improvement in visual acuity with fewer injections required. Amongst various pre-clinical and clinical studies in the literature, a promising approach is the use of suprachoroidal injection with viral and non-viral gene delivery vectors.
View Article and Find Full Text PDFImproving the use of CRISPR/Cas9 gene editing machinery as a cancer therapeutic tool with the help of nanomedicine.
3 Biotech
January 2025
Cancer Nanomedicine Lab, Interdisciplinary Nanotechnology Center, Aligarh Muslim University, Aligarh, UP 202002 India.
CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats-associated protein 9) has revolutionized gene editing tools and paved the way for innovations in medical research for disease diagnosis and treatment. However, better specificity and efficient delivery of this gene machinery make it challenging to successfully edit genes for treating various diseases. This is mainly due to cellular barriers, instability in biological environments, and various off-target effects that prohibit safe and efficient delivery under in vivo conditions.
View Article and Find Full Text PDFNon-viral gene therapy for Leber's congenital amaurosis: progress and possibilities.
Nanomedicine (Lond)
December 2024
Department of Bioengineering, King Fahd University of Petroleum and Minerals (KFUPM), Dhahran, Saudi Arabia.
Leber's congenital amaurosis (LCA) represents a set of rare and pervasive hereditary conditions of the retina that cause severe vision loss starting in early childhood. Targeted treatment intervention has become possible thanks to recent advances in understanding LCA genetic basis. While viral vectors have shown efficacy in gene delivery, they present challenges related to safety, low cargo capacity, and the potential for random genomic integration.
View Article and Find Full Text PDFGene Therapy: Towards a New Era of Medicine.
AAPS PharmSciTech
December 2024
Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, India.
Over the past years, many significant advances have been made in the field of gene therapy and shown promising results in clinical trials conducted. Gene therapy aims at modifying or replacing a defective, inefficient, or nonfunctional gene with a healthy, functional gene by administration of genome material into the cell to cure genetic diseases. Various methods have been devised to do this by using several viral and non-viral vectors which are either administered by in vivo or ex vivo technique.
View Article and Find Full Text PDFHyaluronic acid coating of poly(β-amino ester)/mRNA polyplexes enables ultra-high transfection efficiency.
J Control Release
December 2024
School of Chemical Engineering and Technology, Xi'an Jiaotong University, Xi'an 710049, China. Electronic address:
Article Synopsis
- mRNA is crucial for various biomedical applications, but safe and efficient delivery into target cells is key for its effectiveness.
- A new ternary delivery system was developed using linear poly(β-amino ester)s (LPAEs) coated with hyaluronic acid (HA), which significantly improves mRNA transfection efficiency and cell viability.
- The HA coating enhances the properties of the polyplexes, increasing their ability to interact with cell membranes, suggesting this method could benefit other non-viral mRNA delivery systems.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!